Regeneron expects Q3 2025 pre-tax IPR&D charge of ~$83M, reducing EPS by $0.68

REGENERON PHARMACEUTICALS, INC.

Pre-tax acquired IPR&D charge of ~$83M for Q3 2025, primarily from $80M upfront to Hansoh Pharma.
Charge expected to reduce GAAP and non-GAAP diluted EPS by approximately $0.68 per share.
Preliminary results subject to financial statement closing procedures and may change.
Regeneron does not forecast such IPR&D charges due to uncertainty in timing and magnitude.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.